{"id":"https://openalex.org/W2249200567","doi":"https://doi.org/10.1200/jco.2010.28.15_suppl.8527","title":"A phase II study of imatinib for advanced melanoma patients with KIT aberrations.","display_name":"A phase II study of imatinib for advanced melanoma patients with KIT aberrations.","publication_year":2010,"publication_date":"2010-05-20","ids":{"openalex":"https://openalex.org/W2249200567","doi":"https://doi.org/10.1200/jco.2010.28.15_suppl.8527","mag":"2249200567"},"language":"en","primary_location":{"id":"doi:10.1200/jco.2010.28.15_suppl.8527","doi":"https://doi.org/10.1200/jco.2010.28.15_suppl.8527","is_oa":false,"landing_page_url":"https://doi.org/10.1200/jco.2010.28.15_suppl.8527","pdf_url":null,"source":{"id":"https://openalex.org/S15137598","display_name":"Journal of Clinical Oncology","issn_l":"0732-183X","issn":["0732-183X","1527-7755"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-a","doyens","jufo-3","ki-jl-3","medline","norway-2","poland-200","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310315671","host_organization_name":"Lippincott Williams & Wilkins","host_organization_lineage":["https://openalex.org/P4310315671","https://openalex.org/P4310318547"],"host_organization_lineage_names":["Lippincott Williams & Wilkins","Wolters Kluwer"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Journal of Clinical Oncology","raw_type":"journal-article"},"volume":null,"type":"conference-abstract","indexed_in":["crossref"],"open_access":{"is_oa":false,"oa_status":"closed","oa_url":null,"any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5083141513","display_name":"J. Guo","orcid":"https://orcid.org/0000-0001-9186-3212","observed_orcids":["https://orcid.org/0000-0001-9186-3212"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"J. Guo","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5018372804","display_name":"Lu Si","orcid":"https://orcid.org/0000-0002-2123-9761","observed_orcids":["https://orcid.org/0000-0002-2123-9761"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"L. Si","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":null,"display_name":"Y. Kong","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Y. Kong","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":null,"display_name":"X. w. Xu","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"X. w. Xu","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5023174631","display_name":"Keith T. Flaherty","orcid":"https://orcid.org/0000-0002-3402-0478","observed_orcids":["https://orcid.org/0000-0002-3402-0478"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"K. T. Flaherty","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5026593581","display_name":"Christopher L. Corless","orcid":"https://orcid.org/0000-0003-4871-8364","observed_orcids":["https://orcid.org/0000-0003-4871-8364"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"C. L. Corless","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":null,"display_name":"Y. Y. Zhu","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Y. Y. Zhu","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5017673370","display_name":"L. Li","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"L. Li","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"last","author":{"id":"https://openalex.org/A5081093076","display_name":"H. F. Li","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"H. F. Li","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]}],"institutions":[],"countries_distinct_count":0,"institutions_distinct_count":0,"corresponding_author_ids":[],"corresponding_institution_ids":[],"apc_list":null,"apc_paid":null,"fwci":null,"has_fulltext":false,"cited_by_count":12,"citation_normalized_percentile":null,"cited_by_percentile_year":null,"biblio":{"volume":"28","issue":"15_suppl","first_page":"8527","last_page":"8527"},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T11533","display_name":"Melanoma and MAPK Pathways","score":0.8187999725341797,"subfield":{"id":"https://openalex.org/subfields/1312","display_name":"Molecular Biology"},"field":{"id":"https://openalex.org/fields/13","display_name":"Biochemistry, Genetics and Molecular Biology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},"topics":[{"id":"https://openalex.org/T11533","display_name":"Melanoma and MAPK Pathways","score":0.8187999725341797,"subfield":{"id":"https://openalex.org/subfields/1312","display_name":"Molecular Biology"},"field":{"id":"https://openalex.org/fields/13","display_name":"Biochemistry, Genetics and Molecular Biology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},{"id":"https://openalex.org/T10392","display_name":"Cutaneous Melanoma Detection and Management","score":0.16200000047683716,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T11485","display_name":"Gastrointestinal Tumor Research and Treatment","score":0.0044999998062849045,"subfield":{"id":"https://openalex.org/subfields/2715","display_name":"Gastroenterology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/imatinib","display_name":"imatinib","score":0.9559999704360962},{"id":"https://openalex.org/keywords/kit-mutations","display_name":"KIT mutations","score":0.6389999985694885},{"id":"https://openalex.org/keywords/metastatic-melanoma","display_name":"metastatic melanoma","score":0.9079999923706055},{"id":"https://openalex.org/keywords/acral-melanoma","display_name":"acral melanoma","score":0.9179999828338623},{"id":"https://openalex.org/keywords/mucosal-melanoma","display_name":"mucosal melanoma","score":0.9980000257492065},{"id":"https://openalex.org/keywords/kit-inhibitors","display_name":"KIT inhibitors","score":0.675000011920929},{"id":"https://openalex.org/keywords/braf-v600e-mutation","display_name":"BRAF V600E mutation","score":0.8889999985694885},{"id":"https://openalex.org/keywords/progression-free-survival","display_name":"progression-free survival","score":0.6669999957084656},{"id":"https://openalex.org/keywords/drug-resistance","display_name":"drug resistance","score":0.4740000069141388},{"id":"https://openalex.org/keywords/tyrosine-kinase-inhibitors","display_name":"tyrosine kinase inhibitors","score":0.6949999928474426},{"id":"https://openalex.org/keywords/dose-escalation","display_name":"dose escalation","score":0.3959999978542328},{"id":"https://openalex.org/keywords/toxicity","display_name":"toxicity","score":0.382999986410141},{"id":"https://openalex.org/keywords/asian-patients","display_name":"Asian patients","score":0.5789999961853027},{"id":"https://openalex.org/keywords/liver-metastases","display_name":"liver metastasis","score":0.46700000762939453}],"concepts":[{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.9220758676528931},{"id":"https://openalex.org/C2777583451","wikidata":"https://www.wikidata.org/wiki/Q177094","display_name":"Imatinib","level":3,"score":0.8298518061637878},{"id":"https://openalex.org/C2777658100","wikidata":"https://www.wikidata.org/wiki/Q180614","display_name":"Melanoma","level":2,"score":0.5873656272888184},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.5781116485595703},{"id":"https://openalex.org/C29730261","wikidata":"https://www.wikidata.org/wiki/Q274160","display_name":"Toxicity","level":2,"score":0.5279088616371155},{"id":"https://openalex.org/C31760486","wikidata":"https://www.wikidata.org/wiki/Q7180990","display_name":"Phases of clinical research","level":3,"score":0.5162358283996582},{"id":"https://openalex.org/C2994587330","wikidata":"https://www.wikidata.org/wiki/Q180614","display_name":"Metastatic melanoma","level":3,"score":0.49985742568969727},{"id":"https://openalex.org/C90924648","wikidata":"https://www.wikidata.org/wiki/Q120569","display_name":"Gastroenterology","level":1,"score":0.4533592164516449},{"id":"https://openalex.org/C143998085","wikidata":"https://www.wikidata.org/wiki/Q162555","display_name":"Oncology","level":1,"score":0.44842156767845154},{"id":"https://openalex.org/C2778822529","wikidata":"https://www.wikidata.org/wiki/Q1951525","display_name":"Progressive disease","level":3,"score":0.4268784523010254},{"id":"https://openalex.org/C3019892230","wikidata":"https://www.wikidata.org/wiki/Q177094","display_name":"Imatinib mesylate","level":4,"score":0.4233669936656952},{"id":"https://openalex.org/C146357865","wikidata":"https://www.wikidata.org/wiki/Q1123245","display_name":"Stage (stratigraphy)","level":2,"score":0.42032817006111145},{"id":"https://openalex.org/C121608353","wikidata":"https://www.wikidata.org/wiki/Q12078","display_name":"Cancer","level":2,"score":0.3568812608718872},{"id":"https://openalex.org/C2776694085","wikidata":"https://www.wikidata.org/wiki/Q974135","display_name":"Chemotherapy","level":2,"score":0.31631791591644287},{"id":"https://openalex.org/C502942594","wikidata":"https://www.wikidata.org/wiki/Q3421914","display_name":"Cancer research","level":1,"score":0.20773723721504211},{"id":"https://openalex.org/C151730666","wikidata":"https://www.wikidata.org/wiki/Q7205","display_name":"Paleontology","level":1,"score":0.0},{"id":"https://openalex.org/C2778729363","wikidata":"https://www.wikidata.org/wiki/Q11688946","display_name":"Myeloid leukemia","level":2,"score":0.0},{"id":"https://openalex.org/C86803240","wikidata":"https://www.wikidata.org/wiki/Q420","display_name":"Biology","level":0,"score":0.0}],"mesh":[],"locations_count":1,"locations":[{"id":"doi:10.1200/jco.2010.28.15_suppl.8527","doi":"https://doi.org/10.1200/jco.2010.28.15_suppl.8527","is_oa":false,"landing_page_url":"https://doi.org/10.1200/jco.2010.28.15_suppl.8527","pdf_url":null,"source":{"id":"https://openalex.org/S15137598","display_name":"Journal of Clinical Oncology","issn_l":"0732-183X","issn":["0732-183X","1527-7755"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-a","doyens","jufo-3","ki-jl-3","medline","norway-2","poland-200","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310315671","host_organization_name":"Lippincott Williams & Wilkins","host_organization_lineage":["https://openalex.org/P4310315671","https://openalex.org/P4310318547"],"host_organization_lineage_names":["Lippincott Williams & Wilkins","Wolters Kluwer"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Journal of Clinical Oncology","raw_type":"journal-article"}],"best_oa_location":null,"sustainable_development_goals":[{"display_name":"Good health and well-being","score":1.0,"id":"https://metadata.un.org/sdg/3"}],"sustainable_development_goals_aurora":[{"display_name":"Good health and well-being","score":0.800000011920929,"id":"https://metadata.un.org/sdg/3"}],"study_designs":[],"awards":[],"funders":[],"has_content":{"pdf":false,"grobid_xml":false},"content_urls":null,"referenced_works_count":0,"referenced_works":[],"related_works":["https://openalex.org/W2002247001","https://openalex.org/W2123135404","https://openalex.org/W2070391470","https://openalex.org/W2161653304","https://openalex.org/W2121209161","https://openalex.org/W2037178677","https://openalex.org/W2395417510","https://openalex.org/W2592092676","https://openalex.org/W2045413621","https://openalex.org/W2378015446"],"abstract_inverted_index":{"8527":[0],"Background:":[1],"KIT":[2,32,40,52,58,128,275,309],"is":[3],"an":[4,157],"important":[5],"oncogene":[6],"in":[7,18,35,244,254,260,322,339],"acral":[8],"and":[9,63,117,215,241,247,263,271,289,336],"mucosal":[10],"melanomas,":[11],"which":[12,266],"account":[13,317],"for":[14,299,318],"70%":[15],"of":[16,84,224,273,303,320,332],"melanomas":[17],"Asian":[19],"patients":[20,167,186,196],"(Pts).":[21],"We":[22],"conducted":[23],"a":[24,127,151,295,300],"phase":[25],"II":[26],"study":[27],"(NCT00881049)":[28],"to":[29,88,213,221,345],"test":[30],"the":[31,274,327],"inhibitor":[33],"imatinib":[34,72,239],"metastatic":[36,45,305],"melanoma":[37,48,306],"pts":[38,173,234,307],"with":[39,44,171,308],"aberrations.":[41,310],"Methods:":[42],"Pts":[43,70,204],"or":[46,79,91,130,226],"unresectable":[47],"whose":[49],"tumor":[50],"had":[51,65,126,150,156,162],"aberrations":[53],"(KIT":[54],"mutation":[55,276],"[mut]":[56],"and/or":[57],"gene":[59],"DNA":[60],"amplification":[61],"[amp])":[62],"who":[64,205],"measurable":[66],"disease":[67,77],"were":[68,109,229,242,258,267,285],"enrolled.":[69],"received":[71,198],"400":[73,283],"mg/d":[74],"continually":[75],"until":[76],"progression":[78,97],"intolerable":[80],"toxicity.":[81,118],"The":[82,107],"dosage":[83],"Imatinib":[85,292],"was":[86,98,101],"escalated":[87],"600":[89],"mg":[90,93,284],"800":[92],"per":[94],"day":[95],"if":[96],"observed.":[99],"Response":[100],"assessed":[102],"monthly":[103],"using":[104],"RECIST":[105],"criteria.":[106],"endpoints":[108],"progression-free":[110],"survival":[111],"(PFS),":[112],"overall":[113],"response":[114],"rate":[115],"(ORR)":[116],"Results:":[119],"Of":[120],"390":[121],"cases":[122],"screened,":[123],"67":[124],"(17.4%)":[125],"mut":[129,152],"amp:":[131],"26/137":[132],"(18.9%)":[133],"acral,":[134],"21/110":[135],"(19.1%)":[136],"mucosal,":[137],"9/26":[138],"(34.6%)":[139],"CSD,":[140],"6/75":[141],"(8%)":[142],"NCSD,":[143],"5/42":[144],"(11.9%)":[145],"unknown":[146],"primary.":[147],"41":[148],"(10.5%)":[149],"only;":[153,159],"23":[154],"(5.9%)":[155],"amp":[158],"3":[160,201],"(0.8%)":[161],"both.":[163],"Thus":[164],"far,":[165],"28":[166],"have":[168],"been":[169],"treated":[170],"26":[172],"currently":[174],"evaluable:":[175],"5":[176,232],"stage":[177],"M1a/3":[178],"M1b/20":[179],"M1c;":[180],"median":[181],"prior":[182],"therapies:":[183],"2.":[184],"Six":[185],"(21%)":[187],"achieved":[188],"PR":[189,233],"(5":[190],"mut,":[191],"1":[192],"amp,":[193],"4\u223c10+m);":[194],"nine":[195],"(35%)":[197],"SD":[199],"(\u2265":[200],"m,":[202],"3.5\u223c9+m).":[203],"failed":[206,210,237],"on":[207,211,238],"400mg":[208],"also":[209],"escalation":[212],"600mg":[214],"could":[216],"not":[217],"tolerate":[218],"800mg":[219],"due":[220],"toxicities.":[222],"Samples":[223],"new":[225,256],"progressive":[227],"lesions":[228],"obtained":[230],"from":[231],"after":[235,314],"they":[236],"400mg,":[240],"analyzed":[243],"KIT,":[245],"BRAF":[246,261],"PDGFRA.":[248],"In":[249],"one":[250],"pt":[251],"(emerging":[252],"metastasis":[253],"liver)":[255],"mutations":[257,313],"found":[259],"(V600E)":[262],"PDGFRA":[264],"(W559stop)":[265],"wild-type":[268],"before":[269],"treatment,":[270],"loss":[272],"present":[277],"at":[278,282],"baseline.":[279],"Common":[280],"toxicities":[281],"rash,":[286],"vomiting,":[287],"edema":[288],"myelosuppresion.":[290],"Conclusions:":[291],"(400mg/d)":[293],"provides":[294],"beneficial":[296],"therapeutic":[297],"effect":[298],"significant":[301,342],"proportion":[302],"Chinese":[304],"Acquired":[311],"genetic":[312],"treatment":[315],"may":[316],"emergence":[319],"resistance":[321],"some":[323],"pts.":[324],"Supported":[325],"by":[326],"National":[328],"Natural":[329],"Science":[330],"Foundation":[331],"China":[333],"(30973483),":[334],"985-2-085-113":[335],"Novartis":[337],"Oncology":[338],"China.":[340],"No":[341],"financial":[343],"relationships":[344],"disclose.":[346]},"counts_by_year":[{"year":2019,"cited_by_count":1}],"updated_date":"2026-10-14T16:39:01.820549","created_date":"2025-10-10T00:00:00"}